Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

In vitamin D3 metabolism, we identified 24‐Oxo‐1alpha,23,25‐trihydroxyvitamin D3 (trihydroxyvitamin D3), and its level in F‐ILD was significantly lower compared to that in NF‐ILD (p = 0.0480) (Figure 4 and Table 3).

Source: Untargeted metabolomics analyses. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were eligible for the study if they were greater than 18 years old and determined to have pulmonary fibrosis and/or rare lung disease, including various NF‐ILD, F‐ILD and IPF.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

A pilot metabolomics study across the continuum of interstitial lung disease fibrosis severity

Study design awaiting verification · Physiological Reports · 2024

Original publication title

A pilot metabolomics study across the continuum of interstitial lung disease fibrosis severity

Jiada Zhan; Zachery R. Jarrell; Xin Hu; Jaclyn Weinberg; Michael Orr; Lucian Marts; Dean P. Jones; Young‐Mi Go

© 2024 The Author(s). Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Abstract

Interstitial lung diseases (ILDs) include a variety of inflammatory and fibrotic pulmonary conditions. This study employs high‐resolution metabolomics (HRM) to explore plasma metabolites and pathways across ILD phenotypes, including non‐fibrotic ILD, idiopathic pulmonary fibrosis (IPF), and non‐IPF fibrotic ILD. The study used 80 plasma samples for HRM, and involved linear trend and group‐wise analyses of metabolites altered in ILD phenotypes. We utilized limma one‐way ANOVA and mummichog algorithms to identify differences in metabolites and pathways across ILD groups. Then, we focused on metabolites within critical pathways, indicated by high pathway overlap sizes and low p‐values, for further analysis.

Targeted HRM identified putrescine, hydroxyproline, prolyl‐hydroxyproline, aspartate, and glutamate with significant linear increases in more fibrotic ILD phenotypes, suggesting their role in ILD fibrogenesis. Untargeted HRM highlighted pathway alterations in lysine, vitamin D3, tyrosine, and urea cycle metabolism, all associated with pulmonary fibrosis. In addition, methylparaben level had a significantly increasing linear trend and was higher in the IPF than fibrotic and non‐ILD groups. This study highlights the importance of specific amino acids, metabolic pathways, and xenobiotics in the progression of pulmonary fibrosis.

Authors’ abstract

Abstract

Interstitial lung diseases (ILDs) include a variety of inflammatory and fibrotic pulmonary conditions. This study employs high‐resolution metabolomics (HRM) to explore plasma metabolites and pathways across ILD phenotypes, including non‐fibrotic ILD, idiopathic pulmonary fibrosis (IPF), and non‐IPF fibrotic ILD. The study used 80 plasma samples for HRM, and involved linear trend and group‐wise analyses of metabolites altered in ILD phenotypes. We utilized limma one‐way ANOVA and mummichog algorithms to identify differences in metabolites and pathways across ILD groups. Then, we focused on metabolites within critical pathways, indicated by high pathway overlap sizes and low p‐values, for further analysis.

Targeted HRM identified putrescine, hydroxyproline, prolyl‐hydroxyproline, aspartate, and glutamate with significant linear increases in more fibrotic ILD phenotypes, suggesting their role in ILD fibrogenesis. Untargeted HRM highlighted pathway alterations in lysine, vitamin D3, tyrosine, and urea cycle metabolism, all associated with pulmonary fibrosis. In addition, methylparaben level had a significantly increasing linear trend and was higher in the IPF than fibrotic and non‐ILD groups. This study highlights the importance of specific amino acids, metabolic pathways, and xenobiotics in the progression of pulmonary fibrosis.

Publication and source details

Original title: A pilot metabolomics study across the continuum of interstitial lung disease fibrosis severity

Jiada Zhan; Zachery R. Jarrell; Xin Hu; Jaclyn Weinberg; Michael Orr; Lucian Marts; Dean P. Jones; Young‐Mi Go

Physiological Reports · 2024

* Correspondence
Lucian Marts, Dean P. Jones and Young‐Mi Go, , Department of Medicine, Emory University, Atlanta, Georgia 30322, USA.
Email: lmarts@emory.edu, dpjones@emory.edu and ygo@emory.edu
© 2024 The Author(s). Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.HHS | NIH | National Institute of Environmental Health Sciences (NIEHS) 10.13039/100000066R01 ES031980P30 ES019776HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 10.13039/100000062DK125246

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:35:46.661300+00:00

DOI: 10.14814/phy2.70093 · PMC11489002